Mumbai-based Alkem Laboratories announced today the launch of generic empagliflozin and its combinations in India under the brand name “Empanorm.” The medication, which treats type-2 diabetes, chronic kidney disease, and heart failure, will be priced approximately 80 per cent lower than innovator products.

The shares of Alkem Laboratories Limited were trading today at ₹4,709 down by ₹68.75 or 1.44 per cent on the NSE today at 12.18 pm.

The company is introducing several combination therapies including Empanorm L (empagliflozin and linagliptin), Empanorm Duo and Alsita E (empagliflozin and sitagliptin), and Empanorm M (empagliflozin and metformin).

Alkem’s versions feature an anti-counterfeit security band and include comprehensive patient education materials in multiple languages. The company has also developed a smaller tablet size for patient convenience.

“As we expand and strengthen our chronic portfolio, the introduction of generic empagliflozin in India is an important milestone,” said Dr. Vikas Gupta, Alkem’s CEO. He added that the company plans to leverage its distribution network to improve treatment accessibility nationwide.

Empagliflozin is an SGLT-2 inhibitor that has shown benefits beyond diabetes management, including positive effects on cardiovascular and kidney health.

The fifth-largest pharmaceutical company in India, Alkem operates 19 manufacturing facilities and various R&D centers across India and the US. The company specializes in anti-infectives, gastrointestinal medications, pain management drugs, and supplements, while expanding its chronic therapy offerings.